NEXGEL and STADA AG Announce Expansion of Partnership for North America
MWN-AI** Summary
On July 14, 2025, NEXGEL, Inc. (NASDAQ: NXGL), a provider of high-water-content hydrogel products, announced an expansion of its partnership with STADA Arzneimittel AG, a leading European consumer health company. This collaboration aims to introduce new digestive enzyme formulas and solutions designed to address scars and stretch marks in the North American market.
As part of the expansion, STADA is set to provide NEXGEL with $1 million in non-dilutive capital, which will be utilized to support product launches and marketing initiatives. Adam Levy, CEO of NEXGEL, expressed optimism about this partnership phase, highlighting the opportunity to bring innovative health solutions to North American consumers and emphasizing gratitude for STADA's financial backing that will enhance their joint go-to-market strategy.
STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany, operates with a focus on consumer healthcare products, generics, and specialty pharmaceuticals, distributing its offerings in over 100 countries. In the financial year 2024, STADA reported impressive group sales of €4,059 million, with an adjusted EBITDA of €886 million, showcasing its robust positioning in the healthcare market.
NEXGEL has been a pioneer in developing ultra-gentle, high-water-content hydrogels for over two decades. The company, based in Langhorne, Pennsylvania, boasts a diverse range of OTC and beauty products, including recognized brands like SilverSeal®, Hexagels®, and Kenkoderm®.
This partnership expansion underscores both companies' commitment to enhancing consumer health solutions and reflects their strategy to capture market opportunities in the healthcare sector. Investors are encouraged to follow NEXGEL’s developments as they navigate this promising growth trajectory.
MWN-AI** Analysis
The recent announcement of NEXGEL, Inc.'s expansion of its partnership with STADA Arzneimittel AG marks a significant turning point for the company and its investors. The collaboration aims to introduce new digestive enzyme formulas and solutions for scars and stretch marks across North America, an area with substantial consumer demand. This strategic initiative not only diversifies NEXGEL's product offerings but also strengthens its presence in the competitive healthcare market.
Investor sentiment is likely to be positively influenced by STADA's commitment of $1 million in non-dilutive capital, which supports product launches and marketing efforts. This financial backing is essential for NEXGEL as it navigates market entry strategies, particularly in a region where consumer health trends are increasingly focused on effective, innovative solutions. The backing from a reputable company like STADA—whose 2024 sales reached €4,059 million—provides a robust endorsement of NEXGEL’s growth potential.
NEXGEL's established brand recognition with products like SilverSeal® and Hexagels® positions it favorably to leverage STADA's distribution network, promoting quicker market penetration. As the healthcare sector experiences a rising shift towards specialized consumer products, NEXGEL's focus on high-water-content hydrogels could resonate well with evolving consumer preferences.
From a financial perspective, investors should monitor the execution of the product launch strategy closely. Any delays or setbacks could affect stock performance due to the heightened expectations following this partnership announcement. However, if successful, the market response could lead to increased revenue, making NXGL a potentially lucrative investment opportunity for those interested in the healthcare sector.
In conclusion, while there remain inherent risks—as highlighted by the forward-looking statements in the press release—NEXGEL's strengthened partnership with STADA offers a promising pathway towards growth and market expansion in the North American consumer health landscape. Investors are advised to keep a close watch on the company's developments in the upcoming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks.
As part of the agreement, STADA will advance $1 million to NEXGEL in non-dilutive capital to support product launches and marketing efforts.
“This next phase of our partnership reflects a shared outlook that there is an opportunity in bringing these health solutions to consumers across North America,” said Adam Levy, Chief Executive Officer of NEXGEL. “We are grateful for STADA’s financial support, which will accelerate our joint go-to-market strategy.”
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group sales of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal ® , Hexagels ® , Turfguard ® , Kenkoderm ® and Silly George ® . Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
NEXGEL Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com
FAQ**
How will the expansion of the partnership with STADA influence NEXGEL's revenue, and how does this relate to the potential impact of NEXGEL Inc Warrant NXGLW on investor returns?
What specific strategies will NEXGEL implement to leverage the $1 million non-dilutive capital from STADA, and how might this affect the value of NEXGEL Inc Warrant NXGLW moving forward?
As NEXGEL prepares to launch new digestive enzyme formulas and solutions for scars and stretch marks, what market research supports this initiative, and how could this affect NEXGEL Inc Warrant NXGLW's attractiveness to investors?
Given STADA's established presence in over 100 countries, how might their partnership enhance NEXGEL's market reach, and what implications could this have for the future of NEXGEL Inc Warrant NXGLW and its financial performance?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:
